Literature DB >> 17681368

Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.

Barbara Bohle1, Tamar Kinaciyan, Marianne Gerstmayr, Astrid Radakovics, Beatrice Jahn-Schmid, Christof Ebner.   

Abstract

BACKGROUND: The immunologic mechanisms underlying sublingual immunotherapy (SLIT) are still unclear, particularly the role of regulatory T cells.
OBJECTIVE: We sought to characterize allergen-specific T-cell responses during successful birch pollen SLIT.
METHODS: Proliferation of PBMCs and PBMCs depleted of CD25(+) cells obtained from 9 patients before, after 4 weeks, and after 52 weeks of SLIT was assessed in response to the major birch pollen allergen Bet v 1, the homologous apple allergen Mal d 1, or tetanus toxoid. Allergen-induced cytokine responses and FoxP3 expression of T cells were analyzed by using real-time PCR. The role of IL-10 for regulatory activity of T cells was investigated.
RESULTS: After 4 weeks, higher frequencies of circulating CD4(+)CD25(+) T cells were detected together with increased FoxP3 and IL-10 and reduced IL-4 and IFN-gamma mRNA expression levels compared with those before SLIT. Proliferation to all 3 antigens was markedly reduced but increased significantly after depletion of CD25(+) cells or addition of anti-IL-10 antibodies. After 52 weeks, proliferation in response to Mal d 1 or tetanus toxoid returned to pre-SLIT levels, whereas Bet v 1-induced proliferation remained significantly suppressed and was enhanced by neither depletion of CD25(+) cells nor addition of anti-IL-10 antibodies. In parallel, increased IFN-gamma and reduced IL-4, IL-10, and FoxP3 mRNA expression was detected. Neither TGF-beta levels nor cell-cell contact-mediated suppression of CD4(+)CD25(+) cells changed during the course of SLIT.
CONCLUSION: SLIT induces regulatory T-cell suppression through IL-10 during the early phase and specific nonreactivity and immune deviation of allergen-specific T cells during the later phase of therapy. CLINICAL IMPLICATIONS: SLIT induces immune mechanisms comparable with subcutaneous specific immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681368     DOI: 10.1016/j.jaci.2007.06.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  100 in total

1.  Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study.

Authors:  Julie Wang; Sangita P Patil; Nan Yang; Jimmy Ko; Joohee Lee; Sally Noone; Hugh A Sampson; Xiu-Min Li
Journal:  Ann Allergy Asthma Immunol       Date:  2010-07       Impact factor: 6.347

Review 2.  [Immunological principles of allergen-specific immune therapy].

Authors:  K Blaser
Journal:  HNO       Date:  2008-08       Impact factor: 1.284

Review 3.  [Status and indications for SLIT in comparison to SCIT].

Authors:  B Wedi
Journal:  Hautarzt       Date:  2008-07       Impact factor: 0.751

4.  Oral CD103-CD11b+ classical dendritic cells present sublingual antigen and induce Foxp3+ regulatory T cells in draining lymph nodes.

Authors:  Y Tanaka; H Nagashima; K Bando; L Lu; A Ozaki; Y Morita; S Fukumoto; N Ishii; S Sugawara
Journal:  Mucosal Immunol       Date:  2016-05-11       Impact factor: 7.313

Review 5.  T-cell biology in immunotherapy.

Authors:  John W Steinke; Monica G Lawrence
Journal:  Ann Allergy Asthma Immunol       Date:  2014-01-14       Impact factor: 6.347

Review 6.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 7.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 8.  Dendritic cell modulation as a new interventional approach for the treatment of asthma.

Authors:  Vincent Lombardi; Omid Akbari
Journal:  Drug News Perspect       Date:  2009-10

Review 9.  The identification of potentially pathogenic and therapeutic epitopes from common human allergens.

Authors:  Véronique Schulten; Carla Oseroff; Rafeul Alam; David Broide; Pandurangan Vijayanand; Bjoern Peters; Alessandro Sette
Journal:  Ann Allergy Asthma Immunol       Date:  2012-11-15       Impact factor: 6.347

Review 10.  The cytokine network in asthma and chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.